HUE044469T2 - Anti-foszfolipáz D4 ellenanyagot tartalmazó gyógyszer - Google Patents

Anti-foszfolipáz D4 ellenanyagot tartalmazó gyógyszer

Info

Publication number
HUE044469T2
HUE044469T2 HUE14761423A HUE044469T2 HU E044469 T2 HUE044469 T2 HU E044469T2 HU E14761423 A HUE14761423 A HU E14761423A HU E044469 T2 HUE044469 T2 HU E044469T2
Authority
HU
Hungary
Prior art keywords
phospholipase
medicament
antibody
Prior art date
Application number
Other languages
English (en)
Hungarian (hu)
Inventor
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of HUE044469T2 publication Critical patent/HUE044469T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/916Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HUE14761423 2013-07-30 2014-07-30 Anti-foszfolipáz D4 ellenanyagot tartalmazó gyógyszer HUE044469T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013158258 2013-07-30

Publications (1)

Publication Number Publication Date
HUE044469T2 true HUE044469T2 (hu) 2019-10-28

Family

ID=51493000

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14761423 HUE044469T2 (hu) 2013-07-30 2014-07-30 Anti-foszfolipáz D4 ellenanyagot tartalmazó gyógyszer

Country Status (17)

Country Link
US (2) US20160168266A1 (enExample)
EP (1) EP3027656B1 (enExample)
JP (3) JP6431523B2 (enExample)
KR (1) KR102367760B1 (enExample)
CN (1) CN105745226B (enExample)
AU (1) AU2014297217B2 (enExample)
BR (1) BR112016002001B1 (enExample)
CA (1) CA2919736C (enExample)
DK (1) DK3027656T3 (enExample)
ES (1) ES2736324T3 (enExample)
HU (1) HUE044469T2 (enExample)
MX (1) MX381725B (enExample)
PL (1) PL3027656T3 (enExample)
RU (1) RU2709741C2 (enExample)
SG (2) SG10201800592SA (enExample)
TR (1) TR201910330T4 (enExample)
WO (1) WO2015016386A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
SG10201800592SA (en) * 2013-07-30 2018-03-28 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody
BR112019000544A2 (pt) 2016-07-15 2019-04-24 Takeda Pharmaceutical Company Limited métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática
AU2019208102B2 (en) 2018-01-12 2025-10-09 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-CD38 antibodies
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型tlr7の分析

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
EP1392855A4 (en) * 2000-12-07 2005-05-25 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF VIRAL DISEASES VIA GENE 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
DK2809683T3 (en) * 2012-01-31 2018-12-10 Sbi Biotech Co Ltd ANTI-phospholipase D 4 ANTIBODY
SG10201800592SA (en) * 2013-07-30 2018-03-28 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody

Also Published As

Publication number Publication date
WO2015016386A1 (en) 2015-02-05
MX2016001193A (es) 2016-05-26
JP2016534022A (ja) 2016-11-04
AU2014297217B2 (en) 2020-01-16
MX381725B (es) 2025-03-13
RU2016106708A3 (enExample) 2018-03-30
US20160168266A1 (en) 2016-06-16
JP6843449B2 (ja) 2021-03-17
CA2919736C (en) 2022-03-22
CN105745226A (zh) 2016-07-06
CN105745226B (zh) 2020-03-06
JP2019214621A (ja) 2019-12-19
ES2736324T3 (es) 2019-12-27
BR112016002001A2 (pt) 2017-08-29
SG11201600666SA (en) 2016-02-26
KR20160034934A (ko) 2016-03-30
JP2019014759A (ja) 2019-01-31
CA2919736A1 (en) 2015-02-05
SG10201800592SA (en) 2018-03-28
BR112016002001B1 (pt) 2023-04-25
TR201910330T4 (tr) 2019-07-22
KR102367760B1 (ko) 2022-02-24
DK3027656T3 (da) 2019-08-05
EP3027656A1 (en) 2016-06-08
US20210130493A1 (en) 2021-05-06
RU2016106708A (ru) 2017-09-01
JP6431523B2 (ja) 2018-11-28
PL3027656T3 (pl) 2019-10-31
AU2014297217A1 (en) 2016-02-18
RU2709741C2 (ru) 2019-12-19
EP3027656B1 (en) 2019-06-26

Similar Documents

Publication Publication Date Title
ZA201905426B (en) Drug combinations
SG10201708409VA (en) Medicament device
AU351520S (en) Inhaler
IL240846A0 (en) drug combination
ZA201506252B (en) Syringe
PL3019225T3 (pl) Inhalator
AU352076S (en) Inhaler
PL2978481T3 (pl) Inhalator
SI3035885T1 (sl) Inhalator
GB201300706D0 (en) Antibody
LT3035886T (lt) Inhaliatorius
ZA201508680B (en) Inhaler
SG11201600666SA (en) Medicament comprising anti-phospholipase d4 antibody
SI3016977T1 (sl) Humana protitelesa proti IL-32
GB201320786D0 (en) Medicament
GB201301845D0 (en) Antibody delivery
GB201316662D0 (en) Pharmaceutical Combination
GB201310496D0 (en) Pharmaceutical combinations
GB201301723D0 (en) Pharmaceutical combinations